Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma

INTRODUCTION: Immune checkpoint inhibitors (ICI) have been approved for patients with clear cell renal cell carcinoma (ccRCC), but not all patients benefit from ICI. One reason is the tumor microenvironment (TME) that has substantial influence on patient's prognosis and therapy response. Thus,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stenzel, Philipp J., Schindeldecker, Mario, Tagscherer, Katrin E., Foersch, Sebastian, Herpel, Esther, Hohenfellner, Markus, Hatiboglu, Gencay, Alt, Juergen, Thomas, Christian, Haferkamp, Axel, Roth, Wilfried, Macher-Goeppinger, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2019
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031108/
https://www.ncbi.nlm.nih.gov/pubmed/31881506
http://dx.doi.org/10.1016/j.tranon.2019.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031108/
https://www.ncbi.nlm.nih.gov/pubmed/31881506
http://dx.doi.org/10.1016/j.tranon.2019.11.002

Ejemplares similares